ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 7, 2020

5:00PM-5:50PM: Abstract Number: 0984

Neighborhood Deprivation and Race/Ethnicity Affects COVID-19 Risk and Severity in SLE

SLE – Diagnosis, Manifestations, & Outcomes I: Morbidity (0980–0984)

5:00PM-5:50PM: Abstract Number: 0983

Outcomes Following Antimalarial Withdrawal in Patients with Quiescent Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes I: Morbidity (0980–0984)

5:00PM-5:50PM: Abstract Number: 0952

Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial

Metabolic & Crystal Arthropathies (0950–0954)

5:00PM-5:50PM: Abstract Number: 0965

Repetitive Inhalant Lipopolysaccharide Exposure in the Setting of Arthritis Induction Potentiates Pro-Fibrotic Inflammatory Lung Disease in Mice

RA – Animal Models (0965–0969)

5:00PM-5:50PM: Abstract Number: 0950

The Association Between Gout and Cardiovascular Disease Outcomes: Assessment and Recalibration of Individual-level Primary Prevention Risk Prediction Equations in Approximately 450,000 New Zealanders

Metabolic & Crystal Arthropathies (0950–0954)

5:00PM-5:50PM: Abstract Number: 0951

The Comparative Effect of Exposure to Various Risk Factors on the Risk of Hyperuricaemia: Diet Has a Weak Causal Effect

Metabolic & Crystal Arthropathies (0950–0954)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].